J07BM03 - Papillomavirus (Human Types 6, 11, 16, 18, 31, 33, 45, 52, 58) |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the papillomavirus vaccine, no porphyrinogenic effects are expected.
Chemical description
Protein in the form of virus-like particles produced by recombinant technology.
Therapeutic characteristics
Indicated for protection against contitions caused by nine types of human papillomavirus in individuals from the age of nine. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Medicines Agency (EMA). SmPC Gardasil 9.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Tradenames
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 9 vaccine 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Gardasil 
Vaccines